A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.
Recruiting now. Registry record last updated October 15, 2024.
- Who can join
- Adults 40 to 80, have type 2 diabetes, BMI 25+.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 2 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Type II Diabetes. Also studied in: Atherosclerosis.
Full scientific study title: Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT.
Who can join
Adults 40 to 80, have type 2 diabetes, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Male or female 40 years to 80 years of age at signing of informed consent
- Type 2 DM of minimum 5 years duration with HbA1c ≥7.0% to ≤10.5%
- Body mass index (BMI) ≥25 kilograms per meter squared (kg/m²)
- Presence of two discrete coronary artery plaques with visual diameter stenosis \>20% on CCTA
- At the baseline visit, participants must be on a stable (\>4 weeks) regiment of diabetes medications.
Key exclusion criteria
- Have had a major cardiovascular event within the last 60 days
- Have type 1 diabetes mellitus
- Current use of GLP1-RA
- Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
- Are currently planning treatment for diabetic retinopathy and/or macular edema
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
California1 site
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)Torrance, California
Timeline
Started enrolling: January 2, 2024. Expected completion: May 2026. Last updated on ClinicalTrials.gov: October 15, 2024.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
